Kinomica Announces Multiple Abstracts on its KScan® Precision Oncology Diagnostic Platform to be Presented at the 72nd Annual Meeting of the American Society for Mass Spectrometry

"We are delighted to be able to showcase multiple elements of the KScan® platform and illustrate how these components coalesce into a biomarker discovery capability that provides insights that would otherwise be unobtainable," said Arran Dokal PhD, CTO of Kinomica. "It's well accepted that quantitative phosphoproteomics provides unique biological information that is not captured by other technologies, but any clinical utilization of the technology has been considered challenging. The data we are presenting at ASMS, coupled with the development of predictive signatures for first-line therapies in leukemia and hepatocellular cancer, show the challenges can be overcome and highlight the clinical potential of phosphoproteomics."

"We are delighted to be able to showcase multiple elements of the KScan® platform and illustrate how these components coalesce into a biomarker discovery capability that provides insights that would otherwise be unobtainable," said Arran Dokal PhD, CTO of Kinomica. "It's well accepted that quantitative phosphoproteomics provides unique biological information that is not captured by other technologies, but any clinical utilization of the technology has been considered challenging. The data we are presenting at ASMS, coupled with the development of predictive signatures for first-line therapies in leukemia and hepatocellular cancer, show the challenges can be overcome and highlight the clinical potential of phosphoproteomics."

Abstracts accepted for presentation at ASMS:

"The breadth and depth of data accepted for presentation at this year's ASMS meeting underline our expertise and dedication to developing clinical proteomics for precision medicine," said Tim Fell PhD, Executive Chair of Kinomica.

About Kinomica

Kinomica is a developer of precision oncology diagnostics. The company has developed KScan®, a phosphoproteomic diagnostic platform to help clinicians better realize the full potential of precision medicine by predicting which of the drugs currently approved to treat a disease a particular patient will respond best to, thereby aiding clinical decision making. Learn more at www.kinomica.com and follow us on LinkedIn.

Logo: https://mma.prnewswire.com/media/2422786/4729421/Kinomica_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/kinomica-announces-multiple-abstracts-on-its-kscan-precision-oncology-diagnostic-platform-to-be-presented-at-the-72nd-annual-meeting-of-the-american-society-for-mass-spectrometry-302160590.html